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Neutralization IC50, ng/mL ELISA binding, EC50, ng/mL 
BDBV-GP  EBOV-GP SUDV-GP BDBV-GP  EBOV-GP  SUDV-GP 
BDBV52 IgG1 > > > 27 > > 
BDBV270 IgG1 182 3365 > 154 173 159 
BDBV41 IgG1 93 > > 25 > > 
BDBV43 IgG1 18 506 308 29 22 21 
BDBV289 IgG1 32 588 > 20 29 103 
BDBV259 IgG1 59 > > 26 > > 
BDBV317 IgG1 6 2083 > 9 191 208 
BDBV223 IgG3 <0.1 70 > 22 24 106 
Fig. S1 (related to Fig. 1). A. Amino acid numbers (in parentheses) corresponding to escape mutations 
for the indicated mAb, shown on the map of BDBV GP1 and GP2 [adapted from Lee et al., 2008, Nature 
454(7201):177-182 and Lennemann at al., 2014, mBio. 5(1):e00862-13]. The escape mutations were 
identified by serial passaging of EBOV/BDBV-GP or VSV/BDBV-GP viruses in presence of corresponding 
mAbs and sequencing of viral GP ORFs (see Materials and Methods). SS, signal sequence, RBD, 
receptor-binding domain, GC, glycan cap, MLD, mucin-like domain, CS, furin cleavage site (amino acids 
501/502), IFL, internal fusion loop, HR1, heptad repeat 1, HR2, heptad repeat 2, MPER, membrane-
proximal external region, TM, transmembrane domain, CT, cytoplasmic tail; positions of the first amino 
acid of each domain are indicated. B. Neutralizing and binding potencies of BDBV-specific mAbs against 
BDBV, EBOV and SUDV. IC50 and EC50 values greater than 10,000 ng/mL are indicated by a “>” symbol. 
The figure adapted from Ilinykh et al., 2018 (manuscript in submission).  
B  
A 
54 
CS 
599 672 501 
Vi
ru
s 
tit
er
, l
og
10
P
FU
/m
l  
0
Fig. S2 (related to Fig. 1). THP-1 monocytes infected with EBOV/BDBV-GP in presence of mAb 
release infectious viral particles to the media. Cells were incubated with mAbs at 100 µg/ml, 
infected at an MOI of 1 PFU/cell for 1 hour, washed, and supplemented with fresh medium with no 
mAbs added. In 48 hours, THP-1 supernatants were collected, and virus titer was determined by 
plaque assay. Mean values ±SD based on triplicate samples. Limit of detection: 20 PFU/ml. 
Differences to no antibody control: * p<0.01, ** p<0.001 (Unpaired t-test).  
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Fig. S3 (related to Fig. 1). ADE of additional filovirus species infections. A. Neutralizing and binding 
properties of mAbs isolated from EBOV survivors or two humanized murine mAb components of 
zMapp. B-D, fold increases of infected (eGFP+) THP-1 cells after inoculation with EBOV (B), EBOV/
SUDV-GP (C) or EBOV/MARV-GP (D) in presence of 100 µg/mL (B) or 10 µg/mL (C) of the indicated 
mAb. Mean values ± SD based on triplicate samples. Differences to controls: * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001 (B, C, Unpaired t-test, D, Multiple t-test).  
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(ELISA), 
IC50, µg/mL 
EC50, µg/
mL 
EBOV-68 - 0.036 
EBOV-87 3 0.724 
EBOV-91 - 0.011 
EBOV-141 50 6.159 
EBOV-520 5.738 0.012 
EBOV-333 1 0.016 
13c6 2 0.033 
2G4 0.1 0.187 
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Fig. S4 (related to Fig. 3). ADE depends on the Fc fragment of recombinant IgG. THP-1 cells inoculated 
with EBOV/BDBV-GP (A) or EBOV (B) in the presence of hybridoma-produced BDBV223, which is IgG3 
(IgG3 native), or its recombinant forms of various subclasses at the indicated concentrations. Mean 
values ± SD based on triplicate samples. Differences to no antibody control: * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001 (Multiple t-test). C. The LALA mutation of EBOV-520 IgG1 abrogates ADE in vitro. 
Fluorescent microscopy and flow cytometry analysis of eGFP+ THP-1 cells inoculated with EBOV-eGFP 
at MOI of 1.0 PFU/cell and treated with the indicated concentrations of EBOV-520 IgG1, EBOV-520 IgG1/
LALA, or incubated with no mAb. 
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Fig. S5 (related to Fig. 4). The percentages of infected Vero E6 cells after co-cultivation with 
infected PBMCs. Isolated PBMCs were infected with EBOV/BDBV-GP at an MOI of 1 PFU/
cell. At 24 hours after infection, they were harvested and placed atop of the Vero E6 cell 
monolayers. After 48 hours of co-cultivation, Vero E6 cells were analyzed by flow cytometry. 
Values for individual donors are indicated by symbols, and mean values are indicated by 
horizontal bars.  
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Table S1. Neutralization of EBOV or EBOV/BDBV-GP by Various Forms of BDBV223  
 
 
Form of BDBV223 Subclass 
 
Neutralization activity against indicated virus  
 
(IC50, µg/mL) 
 
 
EBOV 
 
 
EBOV/BDBV-GP 
 
Hybridoma-produced IgG3 0.07 0.0000177 
Recombinant 
IgG1 14.3 0.0004047 
IgG2 0.53 0.0071740 
IgG3 0.00069 0.0006622 
IgG4 122.6 0.0001383 
F(ab′) 0.09 0.0000199    
